%0 Journal Article
%T T Cell Responses to the RTS,S/AS01E and RTS,S/AS02D Malaria Candidate Vaccines Administered According to Different Schedules to Ghanaian Children
%A Daniel Ansong
%A Kwaku P. Asante
%A Johan Vekemans
%A Sandra K. Owusu
%A Ruth Owusu
%A Naana A. W. Brobby
%A David Dosoo
%A Alex Osei-Akoto
%A Kingsley Osei-Kwakye
%A Emmanuel Asafo-Adjei
%A Kwadwo O. Boahen
%A Justice Sylverken
%A George Adjei
%A David Sambian
%A Stephen Apanga
%A Kingsley Kayan
%A Michel H. Janssens
%A Marc J. J. Lievens
%A Aurelie C. Olivier
%A Erik Jongert
%A Patrice Dubois
%A Barbara M. Savarese
%A Joe Cohen
%A Sampson Antwi
%A Brian M. Greenwood
%A Jennifer A. Evans
%A Tsiri Agbenyega
%A Philippe J. Moris
%A Seth Owusu-Agyei
%J PLOS ONE
%D 2012
%I Public Library of Science (PLoS)
%R 10.1371/journal.pone.0018891
%X The Plasmodium falciparum pre-erythrocytic stage candidate vaccine RTS,S is being developed for protection of young children against malaria in sub-Saharan Africa. RTS,S formulated with the liposome based adjuvant AS01E or the oil-in-water based adjuvant AS02D induces P. falciparum circumsporozoite (CSP) antigen-specific antibody and T cell responses which have been associated with protection in the experimental malaria challenge model in adults.
%U http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0018891